Skip Navigation LinksHome > December 2010 - Volume 20 - Issue 9 > Expression of p53, Ki-67, and CD31 Proteins in Endometrial P...
International Journal of Gynecological Cancer:
doi: 10.1111/IGC.0b013e3181f7b33b
Ovarian Cancer

Expression of p53, Ki-67, and CD31 Proteins in Endometrial Polyps of Postmenopausal Women Treated With Tamoxifen

Miranda, Sergimar P. MD*; Traiman, Paulo MD, PhD*; Cândido, Eduardo B. MD†; Lages, Elisa L. MD*; Freitas, Gustavo F. MD*; Lamaita, Rívia Mara MD*; Vidigal, Paula V. T. MD, PhD‡; da Silva Filho, Agnaldo Lopes MD, PhD*†

Collapse Box

Abstract

This study was undertaken to investigate the expression of p53, Ki-67, and CD31 proteins in endometrial polyps of postmenopausal women treated with tamoxifen (TAM). Postmenopausal women with endometrial polyps treated with TAM (n = 20), postmenopausal women with endometrial polyps without hormone use (n = 20), postmenopausal women with atrophic endometrium (n = 20), and postmenopausal women with endometrial adenocarcinoma (n = 20) were prospectively investigated. Tissue samples were immunohistochemically evaluated by monoclonal antibodies for p53, Ki-67, and CD31. The data were analyzed using the Student t test, analysis of variance, and χ2 to evaluate significant differences between the groups. The level of significance was set at P < 0.05. There was no difference in the expression of p53 between the groups (P = 0.067). The expression of Ki-67 was higher in the polyp samples from TAM-treated women compared with those from the women using no hormone (P = 0.0047) and those from the women with atrophic endometrium (P = 0.008). Samples from the women with endometrial cancer was associated with higher Ki-67 expression compared with the polyp samples from TAM-treated women (P = 0.004). The expression of CD31 was higher in the polyp samples of TAM-treated women compared with that of the samples from the women with atrophic endometrium (P < 0.001) and similar to the polyp samples from the women using no hormone (P = 0.319) and to the samples from the women with endometrial cancer (P = 0.418). The use of TAM in postmenopausal women might be associated with increased cellular proliferation in endometrial polyps without interfering angiogenesis or inactivation of tumor suppressor proteins.

Copyright © 2010 by IGCS and ESGO

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/IJGConline

For additional oncology content, visit LWW Oncology Journals on Facebook.